Type 2 diabetes mellitus (T2DM) is one of the most widely spread diseases, affecting around 90% of the patients with diabetes. Metabolomics has proven useful in diabetes research discovering new biomarkers to assist in therapeutical studies and elucidating pathways of interest. However, this technique has not yet been applied to a cohort of patients that have remitted from T2DM.

Marina Mora, together with her supervisor and team members of the GC09 Nutrigenomics. Metabolic Syndrome group at the IMIBIC have published an open access research article about the predictive capacity of metabolites (the products of physical and chemical processes in our body) in T2DM remission.